Additionally, the global KEYFORM-007 trial is investigating the safety and efficacy of the co-formulated favezelimab/pembrolizumab (MK-4280A) in PD-L1-positive CRC patients, with an enrollment of 505 participants. Here, CD274 is linked to colorectal carcinoma.